Correction to: Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation: Bevacizumab dosing strategy in paediatric cancer patients (British Journal of Clinical Pharmacology, (2016), 81, 1, (148-160), 10.1111/bcp.12778);Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation

British Journal of Clinical Pharmacology

Volumn 81, Issue 1, 2016, Pages 148-160

  Han, Kelong ^a   Peyret, Thomas ^b   Quartino, Angelica ^a   Gosselin, Nathalie H ^b   Gururangan, Sridharan ^c   Casanova, Michela ^d   Merks, Johannes H M ^e   Massimino, Maura ^d   Grill, Jacques ^f   Daw, Najat C ^g   Navid, Fariba ^h   Jin, Jin ^a   Allison, David E ^a  

^a GENENTECH INC   (United States)

^b Pharsight A Certara Company   (Canada)

^c DUKE CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bevacizumab; Body surface area; Central nervous system tumour; Dosing strategy; External validation; Paediatric

Indexed keywords

ALBUMIN; BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CENTRAL VOLUME OF DISTRIBUTION; CHILD; CHILDHOOD CANCER; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NEWBORN; PERIPHERAL VOLUME OF DISTRIBUTION; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SARCOMA; BIOLOGICAL MODEL; NEOPLASMS; PRACTICE GUIDELINE; PRESCHOOL CHILD; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MODELS, BIOLOGICAL; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84953351685     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.14000     Document Type: Erratum

References (42)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
3. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
6. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-50.
7. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-43.
8. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J Clin Oncol 2014; 32: 1302-8.
9. Edlund H, Melin J, Parra-Guillen ZP, Kloft C. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet 2015; 54: 35-80.
10. Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 1950; 5: 783-90.
11. Ross EL, Jorgensen J, DeWitt PE, Okada C, Porter R, Haemer M, Reiter PD. Comparison of 3 body size descriptors in critically ill obese children and adolescents: implications for medication dosing. J Pediatr Pharmacol Ther 2014; 19: 103-10.
12. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008 Oct; 62: 779-86.
13. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, Study C's OG. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.
14. Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB 3rd, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 2014; 20: 2783-92.
15. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas - a Pediatric Brain Tumor Consortium study. Neuro Oncol 2014; 16: 310-7.
16. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's Guides (1989-2009). Ellicott City, MD, USA: Icon Development Solutions, 2009.
17. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94.
18. R Core Team (2015). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [online] Available at: http:// www.R-project.org/ (last accessed Aug 15, 2015).
19. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50: 131-42.
20. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry population pharmacokinetics [online]. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM072137.pdf (last accessed Aug 15, 2015).
22. Committee for Medicinal Products for Human Use (CHMP). Guideline on reporting the results of population pharmacokinetic analyses [online]. Doc. ref. CHMP/EWP/ 185990/06, London. Available at http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003067.pdf (last accessed Aug 15, 2015).
23. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
24. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95.
25. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-69.
26. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002; 109: 45-60.
27. Midgley R, Kerr D. Bevacizumab - current status and future directions. Ann Oncol 2005; 16: 999-1004.
28. US. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. The content and format for pediatric use supplements [online]. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm071957.pdf (last accessed Aug 15, 2015).
29. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologicallybased pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013; 52: 83-124.
30. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factoralpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-21.
31. Höcker B, Kovarik JM, Daniel V, Opelz G, Fehrenbach H, Holder M, Hoppe B, Hoyer P, Jungraithmayr TC, Köpf-Shakib S, Laube GF, Müller-Wiefel DE, Offner G, Plank C, SchröderM, Weber LT, Zimmerhackl LB, Tönshoff B. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008; 86: 1234-40.
32. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
33. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
34. Bien E, Rapala M, Krawczyk M, Balcerska A. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas. J Cancer Res Clin Oncol 2010; 136: 293-305.
35. Bien E, Krawczyk M, Izycka-Swieszewska E, Trzonkowski P, Kazanowska B, Adamkiewicz-Drozynska E, Balcerska A. Serum IL-10 and IL-12 levels reflect the response to chemotherapy but are influenced by G-CSF therapy and sepsis in children with soft tissue sarcomas. Postepy Hig Med Dosw (Online) 2013; 67: 517-28.
36. Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y. The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 2013; 53: 160-6.
37. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 493-507.
38. Jastaniah W, Aseeri M. A cross-sectional study comparing variation in body surface area and chemotherapy dosing in pediatric oncology using two different methods. J Oncol Pharm Pract 2010; 16: 189-93.
39. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
40. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62-6.
41. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
42. Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics 2010; 2: 389-418.